Safety and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) in HIV-Infected Subjects 6 Years of Age or Older Who Are Naive to Pneumococcal Vaccine

NCT00962780 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

303

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV Infections
Pneumococcal Infections

Interventions

BIOLOGICAL: 13-valent Pneumococcal Conjugate Vaccine (13vPnC)
BIOLOGICAL: 23-valent Pneumococcal Polysaccharide Vaccine (23vPS)
PROCEDURE: Blood draw
PROCEDURE: Blood draw

Sponsor

Pfizer